TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Percutaneous Neuromodulation Therapy (PNT) With Chronic Low Back Pain Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Low back pain for at least 6 months~* If lower extremity pain present, must be present for at least 3 months~* Visual analog scale (VAS) score for low back pain at least 50 out of 100~* Lumbar or lumbosacral surgical intervention without pain relief~* Central sensitization symptoms~* Agrees to follow randomized treatment plan~* 18 years of age or older~* Signed informed consent form~Exclusion Criteria:~* Significant change to low back or lower extremity pain within 4 weeks prior to enrollment~* Nociceptive and/or neuropathic pain symptoms in the spine due to structural and/or mechanical instabilities~* Three or more lumbar or lumbosacral surgical interventions; one or more surgical interventions in areas other than lumbar or lumbosacral spine~* Three or more lumbar vertebral segments fused~* Lumbar or lumbosacral surgical intervention in last 9 months; areas other than lumbar or lumbosacral in last 12 months~* Any additional surgical intervention required 3 months post-enrollment~* Symptoms consistent with sympathetically-maintained pain~* Evidence of serious neurological deficits or impairments~* Significant changes in pain medications within 4 weeks prior to enrollment~* Psychosocial issues that conflict with valid reporting by patient~* Prior treatment with percutaneous electrical stimulation or sensitivity to electrical stimulation~* Current use of another electrical stimulation device for low back or lower extremity pain~* Current enrollment in another clinical trial within the last 30 days~* Current or prior malignancy or cancer~* Serious or uncontrolled systemic illness~* Body mass index (BMI) greater than 40~* Pregnant or intends to become pregnant during the study~* Implanted medical device~* Relationship with study staff~* Unable to attend study office visits or complete study measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PNT (Type: EXPERIMENTAL): None
- TENS (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ACTIONS - Aortic Counterpulsation to Improve Outcomes in Noncardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 18 years with planned elective major abdominal, noncardiac thoracic, head and neck, vascular, or orthopedic surgery and guideline-treated iscehmic heart disease with left ventricular dysfunction (systolic ejection fraction \< or = 30%)~Exclusion Criteria:~* Unstable coronary syndromes Decompensated or NYHA Class IV heart failure Hemodynamic instability Cardiac biomarker instability Need for surgical procedure interfering with placement of IABP Cardiogenic shock Septic shock Contraindication to IABP use Clinical need for IABP ASA score \> or = 5 Pregnancy Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No IABP (Type: NO_INTERVENTION): Standard of care and no IABP
- Intra-Aortic Balloon Pump (IABP) (Type: ACTIVE_COMPARATOR): Standard of care, IABP inserted \< or = 3 hours before noncardiac surgery, maintained for \> or = 12-24 hours after surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of External Warming During Laparoscopic Bariatric Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible for bariatric surgery~* Surgery time estimated to be \< 2 hours~Exclusion Criteria:~* Previous abdominal surgeries (except laparoscopic cholecystectomies, appendectomies and hysterectomies+/-oophorectomies).~* Surgery time estimated to be more than 2 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- No heating - Study group (Type: EXPERIMENTAL): Patient will undergo bariatric surgery without utilization of external heating device.
- Heating - Control group (Type: OTHER): Patient will undergo bariatric surgery with utilization of external heating device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients with severe COVID-19 (5 point on NIH 8-point ordinal scale).~* Male or female adult ≥18 years of age at time of enrollment;~* Biological samples (not limited to any specific type) collected within 72 hours before randomization is laboratory-confirmed as SARS-CoV-2 infection (PCR or antigen-based diagnostic tests);~* ≤ 10 days since symptoms of COVID-19 onset.~Exclusion Criteria:~* Patients who need non-invasive ventilation or high flow oxygen (i.e., 6 point on the 8-point ordinal scale);~* Patients with critical COVID-19;~* Patients with Severe COVID-19 who received convalescent plasma or COVID-19 vaccine, or anti-SARS-CoV-2 spike (S) protein targeted therapy;~* Alanine-amino transferase (ALT) or aspartate transaminase (AST) is 5 times higher than the upper limit of the normal value;~* Estimated glomerular filtration rate (eGFR) \<30 mL/min or on dialysis {eGFR calculated by Cockcroft-Gault formula (Cockcroft DW, 1976), Male: CrCL (mL/min) = \[(140 - age) × weight (kg)\] × 1/ \[SCr (mg/dL) × 72\]; Female: CrCL (mL/min) = \[(140 - age) × weight (kg)\] × 0.85/ \[SCr (mg/dL) × 72\]}.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SCTA01 Low Dose+BSC (Type: EXPERIMENTAL): SCTA01in a lower dose+best supportive care
- SCTA01 High Dose+BSC (Type: EXPERIMENTAL): SCTA01in a higher dose+best supportive care
- Placebo+BSC (Type: ACTIVE_COMPARATOR): SCTA01 excipients+best supportive care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is an adult (18 years of age or more )~* Subject with epilepsy who has completed 1 of the previous Padsevonil (PSL) studies which allow access to the present study~* Female subjects of child bearing potential must have a serum negative pregnancy test at the Entry Visit, which is confirmed to be negative by urine testing prior to further dispensing at each study visit thereafter. Subjects will be withdrawn from the study as soon as pregnancy is known. Female subjects will use an efficient form of contraception for the duration of the study and for a period of 3 months after their final dose of PSL.~Exclusion Criteria:~* Subject has any severe medical, neurological, or psychiatric condition, or laboratory value which may have an impact on the safety of the subject~* Subject has active suicidal ideation as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the 'Since Last Visit' version of the Columbia-Suicide Severity Rating Scale (C-SSRS)~* Subject has \>2x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \>ULN total bilirubin (\>= l.5x ULN total bilirubin if known Gilbert's syndrome) at the Entry Visit~* Subject has a clinically-significant abnormality on electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study~* Subject has an abnormality on echocardiogram at last echocardiogram assessment, or foreseen in parent study as assessed by central reader that is accompanied by clinical symptoms or a Grade 2\* (or higher)/moderate severity abnormality, or a history of rheumatic heart disease, or other known valvular abnormalities (\*according to the ASE Guidelines, 2017; Zoghbi et al 2017)~* Female subject who plans to be pregnant or is breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Padsevonil (Type: EXPERIMENTAL): Padsevonil will be administered in an open-label manner. The individual starting dose of each subject will be the one at the end of the parent study.~Once subjects enter EP0093 further individual dose adjustments are allowed after 1 week to the extent possible with the combination of tablet strengths available.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Post-market Follow up Study of the 'BPK-S Integration' UC as Primary Implant in the Variants CoCr or Ceramic

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Congenital or acquired knee joint defects/deformation~* Defects or malfunction of the knee joint~* Arthrosis (degenerative, rheumatic)~* Post-traumatic arthritis~* Symptomatic knee instability~* Reconstruction of flexibility~* Patients with metal hypersensitivity (ceramic tibia/femur)~Exclusion Criteria:~* Illnesses which can be treated without using a knee joint implant.~* Acute or chronic infections near the implantation~* Systemic diseases and metabolic disorders~* Serious osteoporosis~* Serious damage to the bone structures that impedes stable implantation of the implant components~* Diseases that impair bone growth, e.g. cancer, renal dialysis, osteopenia, etc.~* Bone tumors in the area of the implant anchoring~* Obesity or overweight of the patient~* Overload of the knee implant to be expected~* Abuse of medication, drug abuse, alcoholism or mental disease~* Pregnancy~* Lack of patient cooperation~* Sensitivity to foreign matter in the implant materials~* Patients under the age of 18~* Patients participating in another trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceramic (Type: None): Patients receiving BPK-S Integration UC implant made from BIOLOX delta ceramic
- CoCr (Type: None): Patients receiving BPK-S Integration UC implant made from CoCr (metal)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First time kidney transplant recipients who receives a kidney from a cadaveric, living related or living unrelated donor~* Age greater than 18 years and less than 75 years~* Caucasian recipients~* Patients with current low panel reactive antibody (PRA) levels (\<10%)~* Patients with signed and dated informed consent~* Women of childbearing potential must have a negative pregnancy test at baseline and agree to use a medically acceptable method of contraception throughout the treatment period.~Exclusion Criteria:~* Other than Caucasian ethnicity~* Patients with HIV+ or~* Patients with HbsAg+ or Hepatitis C positive~* Patients with a history of malignancy in the past 5 years~* Patients with active systemic or localized major infection~* Patients with a history of chronic steroid use for other diseases

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prednisone Withdrawal (Type: EXPERIMENTAL): Participants randomized to the prednisone withdrawal group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was given intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered to participants an inpatient or outpatient for a total of 3 to 5 doses. Participants also began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued indefinitely. The steroids were initially given in the operating room intravenously at time of transplant as Solu-medrol (methylprednisolone)and were then switched to daily oral prednisone doses. The participant's dose of prednisone was rapidly decreased until it was completely eliminated by day 6 post-transplant.
- Prednisone Maintenance (Type: ACTIVE_COMPARATOR): Participants randomized to the prednisone maintenance group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was initiated intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered an inpatient or outpatient for a total of 3 to 5 doses. Participants began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued on them indefinitely. The steroids were initially given intravenously in the operating room at time of transplant as Solu-medrol (methylprednisolone) and were then switched to daily oral prednisone tablets. Participants remained on all drugs according to their doctor's standard of care, and the prednisone was not be eliminated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Study of Familial Forms of Non-atopic Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* index case:~  * Major~ * Lack of respiratory disease documented in the medical record other than asthma~ * Severe Asthma by definition ATS / ERS 2014:~* Treatment with high doses of CI and beta2 agonists for long-acting (B2LDA) or anti leukotriene or theophylline during the previous year or oral corticosteroids (CO) more than 50% from the previous year to prevent loss of control asthma.~* Asthma uncontrolled (at least 1 criteria):~  * ACT \<20 and / or ACQ\> 1.5 (Asthma Control Test)~ * 2 courses or more CO in the previous year~ * 1 hospitalization for asthma in the previous year~ * FEV \<80% predicted despite bronchodilators.~* Examination or medical record to find at least one member of the genetically non-atopic asthma associated family~* Prick negative tests for common allergens, questionnaire seeking negative atopy (SFAR Love) Phadiatop or negative diagnosis of non-atopic asthma confirmed by the adjudication committee~* informed and written consent of the patient to participate in the study~* Affiliated to a social security scheme~Exclusion Criteria:~* Pregnant women~* Minors~  - Known associated respiratory pathologies (COPD, bronchial dilatation, diffuse infiltrating pneumopathy)~* Major Trust~* Subject having demonstrated the inability or refusal to sign an informed consent~Relatives' patients:~* Major~* Related to the 1st and 2nd level of the index case or another member with family~* Related with or without a asthma (atopic or non-atopic)~* Informed and written consent of the patient to participate in the study Affiliated to a social security scheme~Exclusion Criteria:~* Pregnant women~* Minors~* Major Trust~* Subject having demonstrated the inability or refusal to sign an informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- blood sample for genetic evaluation (Type: OTHER): a blood sample is collected once for genetic analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate with metastatic bone disease (by CT, MRI or bone scan) with plans to start or be \< 30 days from beginning androgen deprivation therapy. Patients with lymph node or visceral metastases only are not eligible~* Patients may receive palliative radiation therapy at the investigators discretion during the first 4 weeks of beginning protocol therapy.~Exclusion Criteria:~* No neuroendocrine, small cell or transitional cell cancer of the prostate No abnormal bone metabolism (i.e., Paget's disease, untreated hyperthyroidism, untreated hyperprolactinemia, untreated Cushing's disease).~* No use of calcitonin within 14 days before being registered for protocol therapy or any previous use of bisphosphonates.~* No major surgery within 4 weeks of registration to protocol therapy.~* No adjuvant chemotherapy within 6 months of registration to protocol therapy.~* No previous chemotherapy for metastatic disease.~* No hormonal therapy in the adjuvant setting within 12 months of registration to protocol therapy; previous hormonal therapy must not have exceeded 6 months.~* No prior history of malignancy in the past 5 years with the exception of basal cell and squamous cell carcinoma of the skin.~* No history of allergy or drug reactions to bisphosphonates.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): Daily oral risedronate combined with androgen deprivation
- Placebo Arm (Type: PLACEBO_COMPARATOR): daily oral placebo combined with androgen deprivation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture Treatment for Vertebral Compression Fracture

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Is at least 19 years of age~* Radiographic confirmation of one more subacute or chronic stable vertebral compression fractures (x-ray, computerized tomography, or magnetic resonance imaging)~* Patient-reported pain intensity equal or greater than 4 points on 0 to 10 VAS scale at baseline~* Willingness to participate in the study and provide written informed consent~* Is able to give written consent independently or with a supporter's help~Exclusion Criteria:~* Pathological fracture (malignancy, myeloma, metabolic disease, etc.)~* Spine malformation~* Pregnancy, infection, impaired cognitive function~* Hypersensitive reaction to acupuncture treatment~* Need for surgical treatment~  1. Neurologic deficit: spinal cord injury, cauda equina syndrome~ 2. Unstable fracture: three-column collapse, burst fracture, posterior ligament rupture, distraction fracture~ 3. Scoliotic angle ≥ 12°

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Integrative Treatments (Type: EXPERIMENTAL): This study's arm is single, so all participants will receive acupuncture treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infectious bacterial or fungal keratitis with : size \> 2mm or within the central corneal area ( 3mm of the visual axis ) or with a reaction in anterior chamber.~* Being major responsible.~* Agreement in writing to participate in the study.~* Being affiliated to a national insurance scheme.~Exclusion Criteria:~* Present an infectious keratitis without all the previous criteria.~* Herpes or acanthamoeba keratitis~* preperforated or perforated cornea.~General criteria:~* Pregnant woman.~* Minors(miners).~* Adults under guardianship.~* Patient can not be followed during 3 necessary months.~* French speaking patient.~* Unaffiliated patient in a national insurance scheme.~* HIV infected patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- antibiotic treatment alone (Type: ACTIVE_COMPARATOR): None
- Crosslinking + Antibiotic (Type: EXPERIMENTAL): The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy